Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W) - Concepedia

Concepedia

Publication | Open Access

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

DOI Full Paper Access

118

Citations

27

References

2019

Year

Maxime Dougados, James Cheng‐Chung Wei, Robert Landewé, Joachim Sieper, Xenofon Baraliakos, Filip Van den Bosch, Walter P. Maksymowych, Joerg Ermann, Jessica A. Walsh, Tetsuya Tomita,

Annals of the Rheumatic Diseases

References

	Year	Citations

Page 1